Search

everythinglearnresearchcommunity

for

Search:↓

Injections of follistatin and growth factors can improve hair growth. Specific treatments discussed include Minoxidil, finasteride, and RU58841.

Febron Hair fiber quality has decreased since post-pandemic era, causing fibers to stick to fingers. Users seek better brand recommendations.

The conversation discusses the potential use of HMI 115 for hair loss and whether it could replace or be used alongside finasteride, minoxidil, and RU58841. The user is experiencing scalp inflammation and continued hair shedding despite using finasteride for 8 years.

Pelage is moving to Phase III clinical trials for PP405, a hair loss treatment, with results to be presented at a medical meeting. Users express skepticism and hope, comparing it to existing treatments like Minoxidil and finasteride, while discussing the potential for new hair growth in previously bald areas.

Hair regrowth treatments, including stem cell injections, are discussed, with skepticism about their effectiveness compared to Minoxidil and finasteride. Derma stamping is mentioned as effective when used with Minoxidil, finasteride, and dutasteride.

MCL-1 protein may help maintain hair follicles in the growth phase and prevent miniaturization. There is interest in experimental treatments like exosomes, peptides, or stem cell serums to upregulate MCL-1 for hair loss, especially for those not using minoxidil or finasteride.

A user plans to experiment with creating new hair follicles using methods like derma rolling, applying lithium chloride, tannic acid, and various other substances including caffeine, ketoconazole, and raspberry ketones. They also consider using anti-inflammatories, immunosuppressants, and DHT inhibitors to potentially improve results.

PP405 (Everychem 3HP) may help with hair regrowth, with mixed user experiences. Users often combine it with minoxidil and finasteride, but there are concerns about its efficacy and side effects.

A 57-year-old man with male pattern hair loss and insulin resistance experienced hair regrowth and weight loss after using tirzepatide, without other hair treatments. Dysregulated glucose metabolism is linked to hair loss, with tirzepatide potentially improving hair density by normalizing insulin resistance.

A user shared their hormone levels to gauge if they can use finasteride for hair loss without issues. Their hormone levels are mostly within the reference ranges.

User hoodoomoovoo discusses their interest in stem cell research and its potential for hair loss treatment. They share links to studies and mention ongoing trials, expressing optimism for a future solution to hair loss.

OP shared progress pictures 8 months after FUE surgery in Korea by Dr. Hyun, using Dutasteride. Users discussed the use of Dutasteride over Finasteride in Korea.

The conversation is about hair loss treatment progress using finasteride and GHK-CU over six months. Users discuss application methods and share experiences with GHK-CU and AHK.

User considers adding Alfatradiol to their topical finasteride treatment for hair loss. Others discuss Alfatradiol as a weak estrogen and 5α-reductase inhibitor used for pattern hair loss in men and women.

Hope Medicine's announcement of the HMI-115 Phase II clinical trial for androgenetic alopecia in China; other related trials have been conducted or are ongoing in different countries, including Australia, US, and Europe. There is speculation that the product may be accepted across borders without additional testing.

The user is experiencing reduced hair shedding and increased hair density after using finasteride, minoxidil, derma rolling, granactive retinoid, and Nizoral, while also taking testosterone and aromatase inhibitors. They question if they are a hyper responder to the treatments, despite mixed feedback from others about visible progress.

The user experienced significant hair regrowth using finasteride and minoxidil. They plan to switch to dutasteride for its potency after confirming their body's tolerance to DHT blockers.

HMI 115 is being discussed as a potential hair loss treatment, with skepticism due to past disappointments like cosmeRNA, brezula, and pyrilutamide. The user is questioning if they should be hopeful for new developments in the next six years.

Han Bio claims success in hair multiplication using dermal papilla cells. Treatments discussed include Minoxidil, finasteride, and RU58841.

The conversation is about a user interested in participating in hair cloning clinical trials due to their fine hair and previous positive experience with clinical trials. They are seeking information on how to volunteer for such trials.

User discusses verteporfin for hair regrowth through "super microneedling" and preventing scarring. They mention a case of an old man regrowing hair after a head injury and suggest verteporfin could recreate this result.

The user reports noticeable hair growth after 5 weeks using finasteride, minoxidil, dermarolling, and ketoconazole. They seek confirmation of their progress and question if they are a hyper responder.

The FDA policy change may speed up approval for hair loss drugs like PP405, VDPHL-01, and Breezula by potentially eliminating the need for a second confirmatory Phase 3 trial. Approval timelines could be as early as 2028 for some treatments if Phase 3 results are strong.

The user is using a hair loss regimen involving 2ddr applied twice daily, tretinoin weekly, and occasionally micro-needling. They report feeling increased scalp thickness and seeing some hair growth progress.

Emerging hair loss treatments like PP405, a topical MPC inhibitor, show promise in activating stem cells for hair growth. The conversation seeks information on the development stages and accessibility of these treatments.

The post discusses a user's six-year progress with finasteride and a Follicular Unit Transplant (FUT) for hair loss. The user shared before and after photos in reverse order, leading to confusion, but overall, the community responded positively to the user's hair regrowth.

The conversation discusses the delay in the PP405 Phase 2 study results, now expected by the end of 2025, and skepticism about research practices. There is also mention of optimism for Amplifica's AMP303 and a topical treatment in early testing.

The user has been using dutasteride and finasteride but still experiences hair loss and high DHT levels. They plan to try topical finasteride and RU58841 while continuing dutasteride to see if topicals are more effective.

The conversation discusses the potential updates on the pp405 trial for hair loss, with completion expected by December 2025. Participants express skepticism about new treatments, suggesting continued use of finasteride, while others hope for innovative solutions beyond current medications.

How diffuse unpatterned alopecia (DUPA) is not an invitation to self-diagnose oneself with aggressive AGA and that seeking a specialized dermatologist may help people experiencing hair loss. Treatment options discussed include topical clobetasol propionate, oral minoxidil, and discontinuing finasteride.